Effects of canagliflozin on renal oxygenation evaluated by BOLD MRI in patients with type 2 diabetes
- Conditions
- Type 2 diabetesDiabetic kidney disease
- Registration Number
- JPRN-jRCTs051200047
- Lead Sponsor
- Mori Katsuhito
- Brief Summary
Although results obtained in recent large clinical trials suggest protective effects of SGLT2 inhibitors on the kidneys, the precise mechanisms are largely unknown. We speculated that use of an SGLT2 inhibitor improves renal oxygenation. Thus, the effect of canagliflozin on renal oxygenation was examined using BOLD MRI. The findings indicate that canagliflozin may improve renal cortical oxygenation in patients with T2D.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 14
1) Type 2 diabetes
2) Signed consent form
3) Age >= 20 years and < 80 years
4) HbA1c level >= 6.5% and < 10%
5) Patients without any SGLT2 inhibitors at least 2 weeks before first BOLD MRI (at least 17 days before first canagliflozin administration)
1) Pregnancy or breat-feeding and its possibility
2) Known allergy to canagliflozin
3) Contraindication for MRI (pacemaker or claustrophobia)
4) Past history of recurrent urinary tract or genital infections
5) Nephrotic sydrome
6) Diuretics or NSAIDs
7) Severe renal dysfuntion (eGFR < 30 mL/min/1.73m2) or end-stage renal disease (dialysis) or renal transplantation
8) Renal morphological abnormality such as several cysts, hydronephrosis and abnormal calcification etc.
9) Severe hepatic dysfunction (AST or ALT > triple upper limit of facility criterion)
10) Malignant tumors
11) Severe heart failure (NYHA class III or IV)
12) Patients who participate in any clinical trial except this trial
13) Patients whom principal investigator judges as inappropriate for the trial
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method